Remote Jobs at Celcuity
Celcuity
51 - 200 employees
🧬 Biotechnology
💊 Pharmaceuticals
🔥 Funding within the last year
💰 $500M Post-IPO Debt - Celcuity on 2025-09
Biotechnology • Pharmaceuticals
Celcuity is a clinical-stage biotechnology company developing targeted therapies that comprehensively block the PI3K/AKT/mTOR (PAM) pathway to treat multiple solid tumors. Its lead product candidate, gedatolisib, is a potential first-in-class pan-PI3K and mTORC1/2 inhibitor in late-stage clinical development (including Phase 3 VIKTORIA trials) for HR+/HER2- advanced breast cancer and other indications such as prostate cancer. The company advances a focused pipeline of PAM pathway inhibitors, publishes clinical data, engages with investors and regulators, and is mission-driven to improve outcomes for cancer patients.
Is on LinkedIn?
